-
1
-
-
42249090036
-
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial
-
M. Valgimigli, G. Campo, and G. Percoco Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial JAMA 299 15 2008 1788 1799
-
(2008)
JAMA
, vol.299
, Issue.15
, pp. 1788-1799
-
-
Valgimigli, M.1
Campo, G.2
Percoco, G.3
-
2
-
-
33847766568
-
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents
-
A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 10 2007 1030 1039
-
(2007)
N Engl J Med
, vol.356
, Issue.10
, pp. 1030-1039
-
-
Kastrati, A.1
Mehilli, J.2
Pache, J.3
-
3
-
-
34948904387
-
Effectiveness and safety of drug-eluting stents in Ontario
-
J.V. Tu, J. Bowen, and M. Chiu Effectiveness and safety of drug-eluting stents in Ontario N Engl J Med 357 14 2007 1393 1402
-
(2007)
N Engl J Med
, vol.357
, Issue.14
, pp. 1393-1402
-
-
Tu, J.V.1
Bowen, J.2
Chiu, M.3
-
4
-
-
84876141722
-
Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)
-
M. Valgimigli, G. Campo, and S. Gambetti Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY) Int J Cardiol 165 1 2013 134 141
-
(2013)
Int J Cardiol
, vol.165
, Issue.1
, pp. 134-141
-
-
Valgimigli, M.1
Campo, G.2
Gambetti, S.3
-
6
-
-
78651430525
-
Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents
-
L. Mauri, J.M. Massaro, and S. Jiang Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents JACC Cardiovasc Interv 3 12 2010 1240 1249
-
(2010)
JACC Cardiovasc Interv
, vol.3
, Issue.12
, pp. 1240-1249
-
-
Mauri, L.1
Massaro, J.M.2
Jiang, S.3
-
7
-
-
84867746832
-
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
-
Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet;380(9851):1396-405.
-
Lancet
, vol.380
, Issue.9851
, pp. 1396-1405
-
-
Camenzind, E.1
Wijns, W.2
Mauri, L.3
-
9
-
-
79956278957
-
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in de Novo Native Coronary Artery Lesions)
-
D.E. Kandzari, L. Mauri, and J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 4 5 2011 543 550
-
(2011)
JACC Cardiovasc Interv
, vol.4
, Issue.5
, pp. 543-550
-
-
Kandzari, D.E.1
Mauri, L.2
Popma, J.J.3
-
10
-
-
84876413538
-
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent
-
A.J. Kirtane, M.B. Leon, and M.W. Ball The "Final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent JACC Cardiovasc Interv 6 4 2013 325 333
-
(2013)
JACC Cardiovasc Interv
, vol.6
, Issue.4
, pp. 325-333
-
-
Kirtane, A.J.1
Leon, M.B.2
Ball, M.W.3
-
11
-
-
79959497515
-
Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial
-
T. Pilgrim, L. Raber, and A. Limacher Comparison of titanium-nitride- oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial JACC Cardiovasc Interv 4 6 2011 672 682
-
(2011)
JACC Cardiovasc Interv
, vol.4
, Issue.6
, pp. 672-682
-
-
Pilgrim, T.1
Raber, L.2
Limacher, A.3
-
12
-
-
84867746832
-
Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: A randomised, multicentre, open-label, controlled trial
-
E. Camenzind, W. Wijns, and L. Mauri Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 9851 2012 1396 1405
-
(2012)
Lancet
, vol.380
, Issue.9851
, pp. 1396-1405
-
-
Camenzind, E.1
Wijns, W.2
Mauri, L.3
-
13
-
-
84865309452
-
3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents
-
M. Maeng, H.H. Tilsted, and L.O. Jensen 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents JACC Cardiovasc Interv 5 8 2012 812 818
-
(2012)
JACC Cardiovasc Interv
, vol.5
, Issue.8
, pp. 812-818
-
-
Maeng, M.1
Tilsted, H.H.2
Jensen, L.O.3
-
14
-
-
77957558782
-
Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: The ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial
-
D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 15 2010 1187 1195
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.15
, pp. 1187-1195
-
-
Park, D.W.1
Kim, Y.H.2
Yun, S.C.3
-
15
-
-
72049099355
-
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction
-
C.W. Lee, D.W. Park, and S.H. Lee Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol 104 10 2009 1370 1376
-
(2009)
Am J Cardiol
, vol.104
, Issue.10
, pp. 1370-1376
-
-
Lee, C.W.1
Park, D.W.2
Lee, S.H.3
-
16
-
-
77952744608
-
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents
-
R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 23 2010 2536 2543
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.23
, pp. 2536-2543
-
-
Byrne, R.A.1
Kastrati, A.2
Tiroch, K.3
-
17
-
-
84867050148
-
A new strategy for discontinuation of dual antiplatelet therapy: The RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)
-
B.K. Kim, M.K. Hong, and D.H. Shin A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 15 2012 1340 1348
-
(2012)
J Am Coll Cardiol
, vol.60
, Issue.15
, pp. 1340-1348
-
-
Kim, B.K.1
Hong, M.K.2
Shin, D.H.3
-
18
-
-
84855395899
-
Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial
-
W.C. Kang, T. Ahn, and K. Lee Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 7 8 2011 936 943
-
(2011)
EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
, vol.7
, Issue.8
, pp. 936-943
-
-
Kang, W.C.1
Ahn, T.2
Lee, K.3
-
19
-
-
84860135329
-
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial
-
M. Valgimigli, G. Campo, and M. Monti Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 16 2012 2015 2026
-
(2012)
Circulation
, vol.125
, Issue.16
, pp. 2015-2026
-
-
Valgimigli, M.1
Campo, G.2
Monti, M.3
-
20
-
-
80054972182
-
Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents
-
D.E. Kandzari, C.S. Barker, and M.B. Leon Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents JACC Cardiovasc Interv 4 10 2011 1119 1128
-
(2011)
JACC Cardiovasc Interv
, vol.4
, Issue.10
, pp. 1119-1128
-
-
Kandzari, D.E.1
Barker, C.S.2
Leon, M.B.3
-
21
-
-
72149133094
-
Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial
-
J.S. Kim, I.K. Jang, and C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial JACC Cardiovasc Interv 2 12 2009 1240 1247
-
(2009)
JACC Cardiovasc Interv
, vol.2
, Issue.12
, pp. 1240-1247
-
-
Kim, J.S.1
Jang, I.K.2
Fan, C.3
-
22
-
-
84886954187
-
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
-
[Epub ahead of print]
-
Valgimigli M, Borghesi M, Tebaldi M, et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J; [Epub ahead of print].
-
Eur Heart J
-
-
Valgimigli, M.1
Borghesi, M.2
Tebaldi, M.3
-
23
-
-
84875596758
-
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)
-
M. Valgimigli, M. Borghesi, and M. Tebaldi Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 12 2013 909 919
-
(2013)
Eur Heart J
, vol.34
, Issue.12
, pp. 909-919
-
-
Valgimigli, M.1
Borghesi, M.2
Tebaldi, M.3
|